Exagen Inc. Announces a Collaboration with Hospital for Special Surgery (HSS) for Antiphospholipid Syndrome
August 03 2020 - 4:05PM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
autoimmune diseases, announced today a collaboration with Hospital
for Special Surgery (HSS) in New York City. This well-respected
institution is the world’s leading academic medical center for
autoimmune diseases and musculoskeletal health; for 28 consecutive
years it has been among the top-ranked hospitals in the nation for
rheumatology and orthopedics.
Antiphospholipid syndrome (APS) is an autoimmune clotting
disorder which most commonly increases the risk of blood clots and
pregnancy complications as a result of antiphospholipid antibodies
(aPL). Complement cascade, which is part of the immune system, is
involved in the development of aPL-related clinical problems. This
proof-of-concept clinical study, led by Doruk Erkan, MD, MPH,
rheumatologist at the Barbara Volcker Center for Women and
Rheumatic Diseases at HSS, will investigate complement activation
markers, and additional biomarkers, in different subgroups of
aPL-positive patients.
“We’re pleased to be partnering with HSS. Exagen shares a common
goal with HSS to advance the science of rheumatology through
research, leading to the highest quality patient care and enhancing
the quality of life for all,” said Ron Rocca, President and CEO of
Exagen.
For more information about this study, please contact Joann Vega
at vegaj@hss.edu or call 212-774-2795.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand. Several of these products are based on our
proprietary Cell-Bound Complement Activation Products (CB-CAPs),
technology. CB-CAPs assess the activation of the complement system,
a biological pathway implicated in systemic lupus erythematosus
(SLE). Exagen’s goal is to enable rheumatologists to improve care
for patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis, or RA. Exagen’s model of
integrating testing products and therapeutics
positions Exagen to offer targeted solutions to
rheumatologists and, ultimately, better serve patients. For
more information, please visit www.Exagen.com.
About HSS
HSS is the world’s leading academic medical center focused on
musculoskeletal health. At its core is Hospital for Special
Surgery, nationally ranked No. 1 in orthopedics (for the tenth
consecutive year), No. 3 in rheumatology by U.S. News & World
Report (2019-2020), and named a leader in pediatric orthopedics by
U.S. News & World Report “Best Children’s Hospitals” list
(2019-2020). Founded in 1863, the Hospital has the lowest
complication and readmission rates in the nation for orthopedics,
and among the lowest infection rates. HSS was the first in New York
State to receive Magnet Recognition for Excellence in Nursing
Service from the American Nurses Credentialing Center four
consecutive times. The global standard total knee replacement was
developed at HSS in 1969. An affiliate of Weill Cornell Medical
College, HSS has a main campus in New York City and facilities in
New Jersey, Connecticut and in the Long Island and Westchester
County regions of New York State, as well as in Florida. In
addition to patient care, HSS leads the field in research,
innovation and education. The HSS Research Institute comprises 20
laboratories and 300 staff members focused on leading the
advancement of musculoskeletal health through prevention of
degeneration, tissue repair and tissue regeneration. The HSS Global
Innovation Institute was formed in 2016 to realize the potential of
new drugs, therapeutics and devices. The HSS Education Institute is
a trusted leader in advancing musculoskeletal knowledge and
research for physicians, nurses, allied health professionals,
academic trainees, and consumers in more than 130 countries.
Through HSS Global Ventures, the institution is collaborating with
medical centers and other organizations to advance the quality and
value of musculoskeletal care and to make world-class HSS care more
widely accessible nationally and
internationally. www.hss.edu.
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on the
company’s current beliefs and expectations. Such forward-looking
statements include, but are not limited to, express or implied
statements regarding the proof-of-concept collaborative study and
potential advancement of our science as it compares to complement
activation and other biomarkers in different subgroups of patients
with aPL. The inclusion of forward-looking statements should not be
regarded as a representation by Exagen that any of its
plans will be achieved. Actual results may differ from those set
forth in this press release due to the risks and uncertainties
inherent in Exagen’s business, including, without limitation: the
collaboration with HSS may not lead to discoveries that advance
Exagen’s science or result in an ability to successfully develop
and commercialize a new testing product; and other risks described
in the company’s prior press releases and the company’s filings
with the Securities and Exchange Commission (SEC),
including under the heading “Risk Factors” in the company’s Annual
Report on Form 10-K and any subsequent filings with the SEC.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and Exagen undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, which is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
Investors Westwicke Partners Mike Cavanaugh
Mike.Cavanaugh@westwicke.com 646.677.1838
Company Exagen Inc. Kamal Adawi, Chief
Financial Officer kadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024